Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 507

Document Document Title
WO/2018/223065A1
The present invention provides novel neuromodulatory compounds and compositions thereof. The invention also relates to methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for p...  
WO/2018/076019A1
A novel quantum-based computational process for drug discovery and design was used to identify potential novel liver-stage anti-malarial therapeutic molecules. The approach combined the latest big-data advances in high-throughput bioassa...  
WO/2017/184875A1
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyper...  
WO/2016/118541A1
Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...  
WO/2016/118539A3
Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migrai...  
WO/2015/051307A1
Conjugates of SN-38 that provide optimal drug release rates and minimize the formation of the corresponding glucuronate are described. The conjugates release SN-38 from a polyethylene glycol through a β-elimination mechanism.  
WO/2014/114664A1
The present invention relates to a process for producing 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) including salts and hydrates thereof of general formula (I) from the respective cyclen. Said process further i...  
WO/2014/100354A1
Provided herein are novel methysergide derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders or symptoms thereof, such as, migr...  
WO/2014/078857A1
The invention provides compounds of formula (I) wherein R1-R4 have any of the values defined in the specification, and salts thereof. The compounds are useful as dopamine receptor modulators for the treatment of diseases where modulation...  
WO/2014/070971A3
The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.  
WO/2012/177962A1
Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine u...  
WO/2012/001308A9
The present invention relates to a method for preparing structural analogues of tetracyclic, pentacyclic, and polycyclic ergoline alkaloids, in four steps, from an indole-3-carboxaldehyde, wherein the method includes the following two ke...  
WO/2012/001308A1
The present invention relates to a method for preparing structural analogues of tetracyclic, pentacyclic, and polycyclic ergoline alkaloids, in four steps, from an indole-3-carboxaldehyde, wherein the method includes the following two ke...  
WO/2011/059463A1
This invention relates to deuterated indolocarbazole compounds that are useful in electronic applications. It also relates to electronic devices in which the active layer includes such a deuterated compound.  
WO/2010/045527A1
The present invention is directed to methods and kits for the determining the presence or absence of ergot alkaloids in sample which use chromatographic instrumentation and columns operating at a pressure of 4,000 to 15,000 psi and colum...  
WO/2010/000676A1
The present invention relates to a method for preparing microbiologically produced ergot alkaloids of the following formula (I), comprising the step of: a) extracting the fermentation product occurring during the biological production, s...  
WO/2009/133097A1
A process for producing N-6 demethylated 9,10-dihydrolysergic acid alkyl ester is described, which comprises a step of N-6 demethylation of 9,10-dihydrolysergic acid alkyl esters with chloroformate and wherein the N-6 demethylation step ...  
WO/2009/071607A2
The present invention relates to new Ergot alkaloid derivatives of the general formula (I) or pharmaceutically acceptable salts thereof as well as to the use of specific compounds as selective radical scavengers for neurons.  
WO/2009/071607A3
The present invention relates to new Ergot alkaloid derivatives of the general formula (I) or pharmaceutically acceptable salts thereof as well as to the use of specific compounds as selective radical scavengers for neurons.  
WO2007091039A8
The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.  
WO/2008/104956A2
The present invention relates to processes for the preparation of amorphous cabergoline by agitated thin film drying or spray drying.  
WO/2008/104956A3
The present invention relates to processes for the preparation of amorphous cabergoline by agitated thin film drying or spray drying.  
WO/2008/092881A1
The present invention relates to a cabergoline crystal form L, its preparation from halogenated aromatic solvents and aliphatic hydrocarbons and to pharmaceutical compositions containing the new form.  
WO/2008/049884A8
The present invention relates to a process for producing cabergoline crystal forms. The process comprises preparation of the desired solvate of cabergoline from a solution of cabergoline in chloroaromatic solvents. Afterwards cabergoline...  
WO/2008/049884A1
The present invention relates to a process for producing cabergoline crystal forms. The process comprises preparation of the desired solvate of cabergoline from a solution of cabergoline in chloroaromatic solvents. Afterwards cabergoline...  
WO/2008/043601A3
The present invention relates to a transdermal therapeutic system (TTS) comprising an impermeable covering layer, a matrix containing an ergolin compound of formula (I) or the physiologically compatible salt or derivative thereof, wherei...  
WO/2008/043601A2
The present invention relates to a transdermal therapeutic system (TTS) comprising an impermeable covering layer, a matrix containing an ergolin compound of formula (I) or the physiologically compatible salt or derivative thereof, wherei...  
WO/2007/091039A3
The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.  
WO/2007/091039A2
The present application relates to a novel polymorphic form of cabergoline comprising cabergoline and t-amyl methyl ether, designated Form TAME cabergoline, together with a novel method of producing cabergoline.  
WO/2007/012846A1
A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) and obtaining cabergoline Form I from the solvate. Another aspect of the present invention provides...  
WO2006097345A9
The invention relates to a process for preparing cabergoline of formula (1).  
WO/2006/128658A1
Disclosed are ergoline derivatives, Formula (I), wherein either each of R1 and R2, independently, is H; optionally R10 and/or R11-substituted-phenyl or - phenyl-C1-4alkyl; optionally R10 and/or R11-substituted-heteroaryl or -heteroaryl-C...  
WO2006065448A3
Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.  
WO/2006/100492A3
A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) or 1,3,5- trimethylbenzene and obtaining cabergoline Form I from the solvate. Another aspect of the...  
WO/2006/100492A2
A method of preparing cabergoline Form I, comprising forming a solvate including cabergoline and a p-disubstituted benzene of formula (A) or 1,3,5- trimethylbenzene and obtaining cabergoline Form I from the solvate. Another aspect of the...  
WO/2006/097345A1
The invention relates to a process for preparing cabergoline of formula (1).  
WO/2006/053899A1
The invention relates to a cabergoline preparation method comprising the reaction of a derivative having general formula III, wherein R1 represents a secondary amine function protecting group, with ethyl isocyanate in order to obtain a p...  
WO2005085243A3
A process for preparing cabergoline (I) from ergoline-8ß-carboxylic acid ester (XIII) comprising the following steps. (XIII), (XVI), (XVII), (XVIII), (XIX), (I). The present case also relates to the intermediates (XVI), (XVII), (XVIII) ...  
WO/2005/105796A1
The present invention discloses a method for preparing cabergoline form I by combining cabergoline and a solvent comprising ethylbenzene to form a solvate and obtaining form I from the solvate. Also disclosed in a method for preparing ca...  
WO/2005/085243A2
A process for preparing cabergoline (I) from ergoline-8β-carboxylic acid ester (XIII) comprising the following steps. (XIII), (XVI), (XVII), (XVIII), (XIX), (I). The present case also relates to the intermediates (XVI), (XVII), (XVIII) ...  
WO/2005/082902A1
Lysergic acid is formed in high yields and high quality by isomerizing paspalic acid in a phase separated mixture formed by paspalic acid and a concentrated aqueous metal hydroxide solution.  
WO2004101510B1
Provided are new crystalline Forms, VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline.  
WO2004094368A3
The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medica...  
WO2004101510A3
Provided are new crystalline Forms, VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline.  
WO/2004/101510A2
Provided are new crystalline Forms, VIII, IX, XI, XII, XIV, XV, XVI, XVII, and XVIII of cabergoline. Also provided are novel processes for preparation of cabergoline Form I, Form II, Form VII, and amorphous cabergoline.  
WO/2004/094368A2
The invention provides methods for preparing amorphous physical form of cabergoline, and solvate form A of cabergoline useful in the preparation of the first mentioned physical form. A method for treating a prolactin disorder with medica...  
WO2003076439A3
The invention relates to 1-allyl ergot alkaloids and derivatives thereof, comprising characteristics that are selectively antagonistic towards 5-HT2-receptors, for preventing and alleviating among others, migraine headaches, Parkinson's ...  
WO2003078432A3
A process for the synthesis of pergolide (Formula(I)) (D-6-n-propyl-8beta­methylmercaptomethylergo line) from acid 9,10-dihydrolysergic is herein disclosed. The process can be carried out without isolating most intermediates and is part...  
WO2003078392A3
A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/heptane or toluene/hexane mixture starting from raw cabergoline, followed by recovery and removal of th...  
WO/2003/078392A2
A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/heptane or toluene/hexane mixture starting from raw cabergoline, followed by recovery and removal of th...  

Matches 1 - 50 out of 507